SCHEMBL6475441

SCHEMBL6475441

CC(CNS(=O)(=O)C(C)C)Oc1ccc(-c2ccc(CNC(=O)C(C)C)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRIA4 P48058 8/20 0.42
ERCC1 P07992 1/20 0.41
ERCC4 Q92889 1/20 0.41
MTNR1A P48039 2/20 0.40
MTNR1B P49286 2/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
HDAC1 Q13547 1/20 0.39
PTGES O14684 1/20 0.38
RECQL P46063 1/20 0.38
NR1H4 Q96RI1 1/20 0.38
GRIA1 P42261 1/20 0.37
GRIA2 P42262 1/20 0.37
GRIA3 P42263 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6481138 0.89 MTNR1A (0.50) GRIA4MTNR1AMTNR1BNPC1RAB9A
SCHEMBL6481825 0.89 GRIA4 (0.48) GRIA4MTNR1AMTNR1BMEN1ALDH1A1
SCHEMBL6475842 0.86 GRIA4 (0.46) GRIA4MTNR1AMTNR1BGRIA1GRIA2
SCHEMBL6475448 0.85 ERCC1 (0.39) GRIA4ERCC1ERCC4MTNR1AMTNR1B
SCHEMBL6482318 0.83 GRIA4 (0.53) GRIA4MTNR1AMTNR1BGRIA1GRIA2
SCHEMBL6480681 0.83 GRIA4 (0.48) GRIA4MTNR1AMTNR1BNPC1RAB9A
SCHEMBL6480388 0.83 GRIA4 (0.51) GRIA4NPC1RAB9ARECQLGRIA1
SCHEMBL6766018 0.82 TP53 (0.44) GRIA4MTNR1AMTNR1BGRIA2ALDH1A1
SCHEMBL6482278 0.81 ACACB (0.53) GRIA4MTNR1AMTNR1BMEN1ALDH1A1
SCHEMBL6475284 0.80 GRIA4 (0.53) GRIA4MTNR1AMTNR1BRAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US claimed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US claimed
EP-1265857-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-2001068592-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-09-20 WO claimed
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US disclosed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225266-A1 Sulfonamide derivatives GRIN2A, GRM2, GRIA2 GRIA4 6/4885ERCC1 4671/4885ERCC4 4707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.